Lavitol (Dihydroquercetin from Dahurian Larch)

Lavitol is a standardized dihydroquercetin (taxifolin) extract derived from Dahurian larch (Larix gmelinii) bark, a flavonoid antioxidant that neutralizes free radicals by donating hydrogen atoms to reactive oxygen species. Its primary mechanism involves inhibiting lipid peroxidation and modulating NF-κB inflammatory signaling pathways.

Origin & History

Lavitol is a standardized extract derived from the Dahurian larch tree (Larix gmelinii), containing 97.5% dihydroquercetin (taxifolin) as its primary bioactive compound. The extract is produced through isolation of flavonoid components from larch wood and is used as both a food additive and dietary supplement ingredient.

Historical & Cultural Context

The research does not provide information about traditional or historical use of Lavitol. The ingredient appears to be a modern pharmaceutical development rather than a traditional remedy with documented historical applications.

Health Benefits

• Potent antioxidant activity that may help reduce oxidative stress (supported by preclinical studies) • Anti-inflammatory effects demonstrated through reduction of inflammatory markers in tissue studies (preliminary evidence) • Enhanced wound healing observed in thermal burn models when combined with L-lysine (animal study evidence) • Potential antiviral properties through multiple mechanisms including direct viral protein inhibition (in vitro evidence) • May support metabolic health based on systematic review of weight loss in animal models (meta-analysis of 8 preclinical studies)

How It Works

Dihydroquercetin (taxifolin) scavenges reactive oxygen species including superoxide anions and hydroxyl radicals through its catechol B-ring structure, which readily donates hydrogen atoms to halt lipid peroxidation chain reactions. It inhibits the NF-κB signaling pathway, reducing downstream expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Additionally, taxifolin activates the Nrf2/ARE pathway, upregulating endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase, amplifying cellular oxidative defense beyond direct free radical scavenging.

Scientific Research

The evidence base consists primarily of preclinical safety and efficacy studies, including a comprehensive toxicological assessment covering genotoxicity, 90-day subchronic toxicity, and developmental toxicity studies. A systematic review and meta-analysis (PROSPERO CRD420251129793) evaluated dihydroquercetin's effects on weight loss across 8 animal studies involving 175 subjects. No human randomized controlled trials were identified in the available literature, though a clinical trial for post-COVID-19 therapy was mentioned.

Clinical Summary

Most evidence for Lavitol dihydroquercetin originates from in vitro cell studies and animal models rather than large randomized controlled human trials, limiting the strength of current conclusions. Preclinical studies in rodent thermal burn models demonstrated accelerated wound closure and reduced inflammatory infiltration when dihydroquercetin was applied topically or administered alongside standard care. Small-scale human studies and observational data from Russian clinical practice suggest potential benefits for cardiovascular risk markers and microcirculation, though sample sizes typically ranged from 30–80 participants without robust placebo controls. Overall, the evidence base is preliminary and promising but requires larger, well-designed RCTs to confirm efficacy in humans.

Nutritional Profile

Lavitol (Dihydroquercetin/Taxifolin from Dahurian Larch, Larix gmelinii) is a concentrated bioactive flavonoid extract, not a conventional food ingredient, so macronutrient content is negligible. Key compositional data: Dihydroquercetin (taxifolin) content typically ≥90–98% purity in commercial Lavitol preparations, with the active compound being a flavanonol (dihydroflavonol) with molecular weight 304.25 g/mol. Molecular formula C15H12O7. Contains two chiral centers at C-2 and C-3. Trace phenolic co-extractives from larch heartwood may be present at <2–5%, including aromadendrin and naringenin derivatives. No meaningful protein, fat, carbohydrate, dietary fiber, or caloric contribution at typical supplemental doses (50–300 mg/day). No vitamins or minerals are intrinsic to the extract. Bioavailability: Dihydroquercetin demonstrates moderate oral bioavailability; its 3D structure (saturated C2–C3 bond) compared to quercetin confers greater aqueous solubility (approximately 0.4 mg/mL in water at room temperature) and improved stability under physiological pH conditions. Peak plasma concentration (Tmax) observed at approximately 1–2 hours post-ingestion in available pharmacokinetic data. Undergoes hepatic phase-II conjugation (glucuronidation, sulfation) and limited gut microbiota metabolism to taxifolin-related catechols. Lipid co-administration may enhance absorption. Antioxidant potency: ORAC value estimated at approximately 100–150 μmol TE/mg, substantially higher than standard vitamin C or vitamin E on a per-weight basis in in vitro assays.

Preparation & Dosage

In animal studies, therapeutic doses ranged from 15 mg/kg body weight for single administration to 2000 mg/kg in subchronic toxicity studies. The standardized extract contains 97.5% dihydroquercetin with trace amounts of other flavonoids. Human dosing recommendations are not established based on available clinical evidence. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-lysine, vitamin C, quercetin, resveratrol, green tea extract

Safety & Interactions

Dihydroquercetin is generally considered well-tolerated at typical supplemental doses of 50–200 mg per day, with no serious adverse effects reported in available short-term human studies. Because it may inhibit CYP450 enzymes including CYP3A4 and CYP2C9, caution is warranted when combining it with medications metabolized by these pathways, such as warfarin, statins, or certain anticoagulants, as plasma levels could be altered. Its antioxidant and platelet-modulating properties suggest a theoretical additive bleeding risk when combined with anticoagulant or antiplatelet drugs including aspirin or clopidogrel. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy should be avoided until further research is available.